{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T10:44:21Z","timestamp":1784803461154,"version":"3.55.0"},"reference-count":18,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background and aim: We investigated the clinical outcomes of patients with hepatocellular carcinoma (HCC) who underwent next-generation microwave thermosphere ablation (MTA). Methods: A total of 429 patients with 607 HCCs (maximum tumor diameter \u226440 mm) were included. We defined the following areas of the liver as those where MTA therapy is difficult to perform: caudate lobe and areas near the primary and secondary branches of the intrahepatic portal vein, inferior vena cava, gallbladder, heart, duodenum, abdominal esophagus, collateral veins around the liver, and spleen. Factors which predisposed patients to local tumor recurrence in the context of tumor location and complications were examined. Results: The primary etiologies of HCC were hepatitis-related: 259 (60.4%) cases of HCV, 31 (7.3%) cases of HBV, and two instances of both. Median maximum tumor diameter was 15.0 (interquartile range, 10.0\u201321.0) mm. There were 86 tumors in areas of the liver where MTA is difficult. The most common area was near the primary and secondary branches of the intrahepatic portal vein (26 nodules). The cumulative local tumor recurrence rates at 1, 2, and 3 years were 4.4%, 8.0%, and 8.5%, respectively. The cumulative local tumor recurrence rate differed significantly by tumor size group: 6.6%, 13.8%, and 29.4% at three years in the \u226420 mm group (n = 483), 20\u201330 mm group (n = 107), and \u226530 mm group (n = 17), respectively (p &lt; 0.001). The cumulative local tumor recurrence rate was similar despite difficult-to-treat status (p = 0.169). In the multivariable analysis, tumor size (&gt;15 mm) (hazard ratio [HR], 2.15; 95% confidence interval [CI], 1.11\u20134.16; p = 0.023) and ablative margin (&lt;3 mm) (HR, 2.94; 95% CI, 1.52\u20135.71; p = 0.001) were significantly associated with local tumor recurrence. Only tumor size (&gt;15 mm) (odds ratio, 3.41 95% CI, 1.53\u20137.84; p = 0.026) was significantly associated with complications. Conclusions: MTA is a safe and effective local ablation therapy for HCC, even for tumors located in areas of the liver where local ablation therapy is difficult.<\/jats:p>","DOI":"10.3390\/jcm12247577","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T08:47:26Z","timestamp":1702025246000},"page":"7577","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Outcomes of Next-Generation Microwave Thermosphere Ablation for Hepatocellular Carcinoma with Primarily Hepatitis-Related Etiology"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5065-9669","authenticated-orcid":false,"given":"Shinichiro","family":"Nakamura","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, 1-12-1 Shimoteno, Himeji 670-8540, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, 1-12-1 Shimoteno, Himeji 670-8540, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Sue","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, 1-12-1 Shimoteno, Himeji 670-8540, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, 1-12-1 Shimoteno, Himeji 670-8540, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, 1-12-1 Shimoteno, Himeji 670-8540, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Muramatsu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, 1-12-1 Shimoteno, Himeji 670-8540, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Morii","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, 1-12-1 Shimoteno, Himeji 670-8540, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, 1-12-1 Shimoteno, Himeji 670-8540, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: The BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin. Liver Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/hep.31327","article-title":"Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference","volume":"73","author":"Llovet","year":"2021","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1148\/radiol.11110144","article-title":"Local-regional treatment of hepatocellular carcinoma","volume":"262","author":"Lencioni","year":"2012","journal-title":"Radiology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jhep.2008.01.022","article-title":"Novel advancements in the management of hepatocellular carcinoma in 2008","volume":"48","author":"Llovet","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/j.gastro.2005.04.009","article-title":"A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma","volume":"129","author":"Shiina","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00535-003-1280-y","article-title":"Local ablation therapy for hepatocellular carcinoma: Current status and future perspectives","volume":"39","author":"Kudo","year":"2004","journal-title":"J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/hep.23965","article-title":"Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: A long-term cohort study","volume":"53","author":"Rossi","year":"2011","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1016\/j.jvir.2010.04.007","article-title":"Microwave tumor ablation: Mechanism of action, clinical results, and devices","volume":"21","author":"Lubner","year":"2010","journal-title":"J. Vasc. Interv. Radiol. JVIR"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: An update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hepr.13892","article-title":"Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines)","volume":"53","author":"Hasegawa","year":"2023","journal-title":"Hepatol. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000514174","article-title":"Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/02656736.2015.1127434","article-title":"Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis","volume":"32","author":"Facciorusso","year":"2016","journal-title":"Int. J. Hyperth."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3350\/cmh.2021.0136","article-title":"New next-generation microwave thermosphere ablation for small hepatocellular carcinoma","volume":"27","author":"Tamai","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1055\/s-0035-1564811","article-title":"The Emprint Ablation System with Thermosphere Technology: One of the Newer Next-Generation Microwave Ablation Technologies","volume":"32","author":"Alonzo","year":"2015","journal-title":"Semin. Interv. Radiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.ejso.2015.08.171","article-title":"Temperature monitoring during microwave ablation in ex vivo porcine livers","volume":"41","author":"Saccomandi","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.medengphy.2019.02.007","article-title":"Ex vivo validation of microwave thermal ablation simulation using different flow coefficients in the porcine liver","volume":"66","author":"Schreiner","year":"2019","journal-title":"Med. Eng. Phys."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/24\/7577\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:35:21Z","timestamp":1760132121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/24\/7577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":18,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["jcm12247577"],"URL":"https:\/\/doi.org\/10.3390\/jcm12247577","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]}}}